But I also understand why Sangamo has taken it very slow on beta thal. Instead of going forward with inconsistent cell processing tech and uneven product, they have probably been perfecting the process behind the scenes. By doing that, Sangamo avoided the inevitable share price plunge that comes with disappointing bottom line clinical trial results. Instead, Sangamo/Sanofi now have the opportunity to surprise the markets to the upside with what has hopefully been going on behind the curtain. Fabry just seems plain old SLOW for no other reason than slow recruiting due to COVID.
We should be seeing a PR after markets close today announcing Q3 conference call.